nach oben

Current Addiction Reports

Erschienen in:

01.06.2019 | Tobacco (K Garrison, Section Editor)

Mechanisms and Clinical Features of Co-Occurring Opioid and Nicotine Use

verfasst von: Sarah D. Lichenstein, Yasmin Zakiniaeiz, Sarah W. Yip, Kathleen A. Garrison

Erschienen in: Current Addiction Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review the literature addressing shared pathophysiological and clinical features of opioid and nicotine use to inform etiology and treatment, and highlight areas for future research.

Recent Findings

Opioid and nicotine use co-occur at an alarmingly high rate, and this may be driven in part by interactions between the opioid and cholinergic systems underlying drug reward and the transition to dependence. Pain, among other shared risk factors, is strongly implicated in both opioid and nicotine use and appears to play an important role in their co-occurrence. Additionally, there are important sex/gender considerations that require further study. Regarding treatment, smoking cessation can improve treatment outcomes in opioid use disorder, and pharmacological approaches that target the opioid and cholinergic systems may be effective for treating both classes of substance use disorder.

Summary

Understanding overlapping etiological and pathophysiological mechanisms of opioid and nicotine use can aid in understanding their co-occurrence and guiding their treatment.

Gomes T, Tadrous M, Mamdani MM, Paterson J, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217. https://doi.org/10.1001/jamanetworkopen.2018.0217.CrossRefPubMedPubMedCentral

Klaman SL, Isaacs K, Leopold A, Perpich J, Hayashi S, Vender J, et al. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med. 2017;11(3):178–90. https://doi.org/10.1097/adm.0000000000000308.CrossRefPubMedPubMedCentral

Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the Global Burden of Disease 2010 study. Addiction. 2014;109(8):1320–33. https://doi.org/10.1111/add.12551.CrossRefPubMed

Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113(10):1905–26. https://doi.org/10.1111/add.14234.CrossRefPubMed

• Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821–6. https://doi.org/10.1001/jamapsychiatry.2014.366 . This study reports on changes in demographic and clinical characteristics of patients entering substance abuse treatment for OUD.CrossRefPubMed

Muhuri P, Gfroerer J, Davies M. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. SAMHSA. 2013. <http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.htm>. Accessed 19 April 2019.

Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A, Wang Y, et al. Increases in fentanyl-related overdose deaths—Florida and Ohio, 2013–2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):844–9. https://doi.org/10.15585/mmwr.mm6533a3.CrossRefPubMed

Marshall BDL, Krieger MS, Yedinak JL, Ogera P, Banerjee P, Alexander-Scott NE, et al. Epidemiology of fentanyl-involved drug overdose deaths: a geospatial retrospective study in Rhode Island, USA. Int J Drug Policy. 2017;46:130–5. https://doi.org/10.1016/j.drugpo.2017.05.029.CrossRefPubMed

World Health Organization. WHO global report: mortality attributable to tobacco. Geneva, Switzerland. 2012. http://www.who.int/tobacco/publications/surveillance/rep_mortality_attributable/en. Accessed 04/14/15.

10.

Goodchild M, Nargis N, Tursan d'Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control. 2018;27(1):58–64. https://doi.org/10.1136/tobaccocontrol-2016-053305.CrossRefPubMed

11.

Ahluwalia I, Smith T, Arrazola R, Palipudi K, Garcia de Quevedo I, Prasad V et al. Current tobacco smoking, quit attempts, and knowledge about smoking risks among persons aged ≥15 years—Global Adult Tobacco Survey, 28 Countries. 2008–20162018.

12.

Fiore M, JaÈn C, Baker T, Bailey W, Benowitz N, Curry S et al. Treating tobacco use and dependence: 2008 update—clinical practice guidelines. US Department of Health and Human Services, Rockville, MD. 2008. http://bphc.hrsa.gov/buckets/treatingtobacco.pdf. Accessed Sept 1 2015.

13.

Ditre JW, Brandon TH, Zale EL, Meagher MM. Pain, nicotine, and smoking: research findings and mechanistic considerations. Psychol Bull. 2011;137(6):1065–93. https://doi.org/10.1037/a0025544.CrossRefPubMedPubMedCentral

14.

World Health Organization, editor. Electronic nicotine delivery systems. WHO Framework Convention on Tobacco Control; 2014 13–18 October 2014; Moscow, Russian Federation.

15.

Zirakzadeh A, Shuman C, Stauter E, Hays JT, Ebbert JO. Cigarette smoking in methadone maintained patients: an up-to-date review. Curr Drug Abuse Rev. 2013;6(1):77–84. https://doi.org/10.2174/1874473711306010009.CrossRefPubMed

16.

Soyka M. Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2015;21(2):78–87. https://doi.org/10.1159/000363232.CrossRefPubMed

17.

Baca CT, Yahne CE. Smoking cessation during substance abuse treatment: what you need to know. J Subst Abus Treat. 2009;36(2):205–19. https://doi.org/10.1016/j.jsat.2008.06.003.CrossRef

18.

• Yoon JH, Lane SD, Weaver MF. Opioid analgesics and nicotine: more than blowing smoke. J Pain Palliat Care Pharmacother. 2015;29(3):281–9. https://doi.org/10.3109/15360288.2015.1063559 This review discusses interactions between nicotine and opioids among individuals prescribed opioids for pain. CrossRefPubMed

19.

Guydish J, Passalacqua E, Tajima B, Chan M, Chun J, Bostrom A. Smoking prevalence in addiction treatment: a review. Nicotine Tob Res. 2011;13(6):401–11. https://doi.org/10.1093/ntr/ntr048.CrossRefPubMedPubMedCentral

20.

John U, Alte D, Hanke M, Meyer C, Völzke H, Schumann A. Tobacco smoking in relation to analgesic drug use in a national adult population sample. Drug Alcohol Depend. 2006;85(1):49–55.CrossRef

21.

Young-Wolff KC, Klebaner D, Weisner C, Von Korff M, Campbell CI. Smoking status and opioid-related problems and concerns among men and women on chronic opioid therapy. Clin J Pain. 2017;33(8):730–7. https://doi.org/10.1097/ajp.0000000000000461.CrossRefPubMedPubMedCentral

22.

Morasco BJ, Turk DC, Donovan DM, Dobscha SK. Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013;127(1):193–9. https://doi.org/10.1016/j.drugalcdep.2012.06.032.CrossRefPubMed

23.

• Zale EL, Dorfman ML, Hooten WM, Warner DO, Zvolensky MJ, Ditre JW. Tobacco smoking, nicotine dependence, and patterns of prescription opioid misuse: results from a nationally representative sample. Nicotine Tob Res. 2015;17(9):1096–103. https://doi.org/10.1093/ntr/ntu227 This study provides epidemiological evidence for the association between smoking and opioid medication misuse in a nationally representative sample. CrossRefPubMed

24.

Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol. 2010;20(12):890–7. https://doi.org/10.1016/j.annepidem.2010.03.010.CrossRefPubMed

25.

Frosch DL, Shoptaw S, Nahom D, Jarvik ME. Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Exp Clin Psychopharmacol. 2000;8(1):97–103. https://doi.org/10.1037/1064-1297.8.1.97.CrossRefPubMed

26.

Parker MA, Streck JM, Sigmon SC. Associations between opioid and nicotine dependence in nationally representative samples of United States adult daily smokers. Drug Alcohol Depend. 2018;186:167–70. https://doi.org/10.1016/j.drugalcdep.2018.01.024.CrossRefPubMedPubMedCentral

27.

Tuesta LM, Fowler CD, Kenny PJ. Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol. 2011;82(8):984–95. https://doi.org/10.1016/j.bcp.2011.06.026.CrossRefPubMedPubMedCentral

28.

Klein LC. Effects of adolescent nicotine exposure on opioid consumption and neuroendocrine responses in adult male and female rats. Exp Clin Psychopharmacol. 2001;9(3):251–61. https://doi.org/10.1037/1064-1297.9.3.251.CrossRefPubMed

29.

Xue Y, Domino EF. Tobacco/nicotine and endogenous brain opioids. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32(5):1131–8. https://doi.org/10.1016/j.pnpbp.2007.12.012.CrossRef

30.

Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev. 2010;35(2):220–31. https://doi.org/10.1016/j.neubiorev.2010.02.006.CrossRefPubMedPubMedCentral

31.

• Kuwabara H, Heishman SJ, Brasic JR, Contoreggi C, Cascella N, Mackowick KM, et al. Mu opioid receptor binding correlates with nicotine dependence and reward in smokers. PLoS One. 2014;9(12):e113694. https://doi.org/10.1371/journal.pone.0113694 This study demonstrates associations between MOR availability and nicotine reward and dependence severity among human subjects. CrossRefPubMedPubMedCentral

32.

Kishioka S, Kiguchi N, Kobayashi Y, Saika F. Nicotine effects and the endogenous opioid system. J Pharmacol Sci. 2014;125(2):117–24. https://doi.org/10.1254/jphs.14R03CP.CrossRefPubMed

33.

Merrer JL, Becker JAJ, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89(4):1379–412. https://doi.org/10.1152/physrev.00005.2009.CrossRefPubMedPubMedCentral

34.

Talka R, Salminen O, Whiteaker P, Lukas RJ, Tuominen RK. Nicotine–morphine interactions at α4β2, α7 and α3⁎ nicotinic acetylcholine receptors. Eur J Pharmacol. 2013;701(1):57–64. https://doi.org/10.1016/j.ejphar.2013.01.005.CrossRefPubMed

35.

Vihavainen T, Mijatovic J, Piepponen TP, Tuominen RK, Ahtee L. Effect of morphine on locomotor activity and striatal monoamine metabolism in nicotine-withdrawn mice. Behav Brain Res. 2006;173(1):85–93. https://doi.org/10.1016/j.bbr.2006.06.004.CrossRefPubMed

36.

Vihavainen T, Piltonen M, Tuominen RK, Korpi ER, Ahtee L. Morphine–nicotine interaction in conditioned place preference in mice after chronic nicotine exposure. Eur J Pharmacol. 2008;587(1):169–74. https://doi.org/10.1016/j.ejphar.2008.03.028.CrossRefPubMed

37.

Shi MDMPHY, Weingarten MDTN, Mantilla MDPDCB, Hooten MDWM, Warner MDDO. Smoking and pain: pathophysiology and clinical implications. Anesthesiology. 2010;113(4):977–92. https://doi.org/10.1097/ALN.0b013e3181ebdaf9.CrossRefPubMed

38.

Zarrindast M-R, Faraji N, Rostami P, Sahraei H, Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav. 2003;74(2):363–9. https://doi.org/10.1016/S0091-3057(02)01002-X.CrossRefPubMed

39.

Volkow ND, McLellan AT. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–63. https://doi.org/10.1056/NEJMra1507771.CrossRefPubMed

40.

Lanz S, Seifert F, Maihofner C. Brain activity associated with pain, hyperalgesia and allodynia: an ALE meta-analysis. J Neural Transm (Vienna, Austria: 1996). 2011;118(8):1139–54. https://doi.org/10.1007/s00702-011-0606-9.CrossRef

41.

Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacol. 2018. https://doi.org/10.1038/s41386-018-0232-4.

42.

Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86. https://doi.org/10.7326/m14-2559.CrossRefPubMed

43.

Boscarino JA, Rukstalis MR, Hoffman SN, Han JJ, Erlich PM, Ross S, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis. 2011;30(3):185–94. https://doi.org/10.1080/10550887.2011.581961.CrossRefPubMed

44.

Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. J Clin Psychiatry. 2009;70(9):1213–8.CrossRef

45.

Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370–8. https://doi.org/10.1001/jama.289.18.2370.CrossRefPubMed

46.

Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manag. 2000;19(1):53–62.CrossRef

47.

Dunn KE, Brooner RK, Clark MR. Severity and interference of chronic pain in methadone-maintained outpatients. Pain Med. 2014;15(9):1540–8. https://doi.org/10.1111/pme.12430.CrossRefPubMed

48.

Barry DT, Beitel M, Cutter CJ, Garnet B, Joshi D, Rosenblum A, et al. Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients. J Pain. 2011;12(1):22–8. https://doi.org/10.1016/j.jpain.2010.04.006.CrossRefPubMed

49.

Plesner K, Jensen HI, Hojsted J. Smoking history, nicotine dependence and opioid use in patients with chronic non-malignant pain. Acta Anaesthesiol Scand. 2016;60(7):988–94. https://doi.org/10.1111/aas.12741.CrossRefPubMed

50.

Orhurhu VJ, Pittelkow TP, Hooten WM. Prevalence of smoking in adults with chronic pain. Tob Induc Dis. 2015;13(1):17. https://doi.org/10.1186/s12971-015-0042-y.CrossRefPubMedPubMedCentral

51.

Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The association between smoking and low back pain: a meta-analysis. Am J Med. 2010;123(1):87 e7–35. https://doi.org/10.1016/j.amjmed.2009.05.028.CrossRef

52.

Hahn EJ, Rayens MK, Kirsh KL, Passik SD. Brief report: pain and readiness to quit smoking cigarettes. Nicotine Tob Res. 2006;8(3):473–80. https://doi.org/10.1080/14622200600670355.CrossRefPubMed

53.

Ditre JW, Kosiba JD, Zale EL, Zvolensky MJ, Maisto SA. Chronic pain status, nicotine withdrawal, and expectancies for smoking cessation among lighter smokers. Ann Behav Med. 2016;50(3):427–35. https://doi.org/10.1007/s12160-016-9769-9.CrossRefPubMedPubMedCentral

54.

Hooten WM. Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc. 2016;91(7):955–70. https://doi.org/10.1016/j.mayocp.2016.04.029.CrossRefPubMed

55.

Kosiba JD, Zale EL, Ditre JW. Associations between pain intensity and urge to smoke: testing the role of negative affect and pain catastrophizing. Drug Alcohol Depend. 2018;187:100–8. https://doi.org/10.1016/j.drugalcdep.2018.01.037.CrossRefPubMedPubMedCentral

56.

Dhingra LK, Homel P, Grossman B, Chen J, Scharaga E, Calamita S, et al. Ecological momentary assessment of smoking behavior in persistent pain patients. Clin J Pain. 2014;30(3):205–13. https://doi.org/10.1097/AJP.0b013e31829821c7.CrossRefPubMed

57.

Parkerson HA, Asmundson GJG. The role of pain intensity and smoking expectancies on smoking urge and behavior following experimental pain induction. Drug Alcohol Depend. 2016;164:166–71. https://doi.org/10.1016/j.drugalcdep.2016.05.007.CrossRefPubMed

58.

•• Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA. Acute analgesic effects of nicotine and tobacco in humans: a meta-analysis. Pain. 2016;157(7):1373–81. https://doi.org/10.1097/j.pain.0000000000000572 Meta-analysis of acute nicotine effect on pain in line with proposed reciprocal model of pain and smoking as a positive feedback loop that results in greater pain, increased smoking, and maintenance of tobacco addiction. CrossRefPubMedPubMedCentral

59.

Weingarten TN, Moeschler SM, Ptaszynski AE, Hooten WM, Beebe TJ, Warner DO. An assessment of the association between smoking status, pain intensity, and functional interference in patients with chronic pain. Pain Physician. 2008;11:643–53.PubMed

60.

Ditre JW, Brandon TH. Pain as a motivator of smoking: effects of pain induction on smoking urge and behavior. J Abnorm Psychol. 2008;117(2):467–72. https://doi.org/10.1037/0021-843X.117.2.467.CrossRefPubMedPubMedCentral

61.

Nakajima M, Al’Absi M. Nicotine withdrawal and stress-induced changes in pain sensitivity: a cross-sectional investigation between abstinent smokers and nonsmokers. Psychophysiology. 2014;51(10):1015–22. https://doi.org/10.1111/psyp.12241.CrossRefPubMedPubMedCentral

62.

LaRowe LR, Kosiba JD, Zale EL, Ditre JW. Effects of nicotine deprivation on current pain intensity among daily cigarette smokers. Exp Clin Psychopharmacol. 2018;26(5):448–55. https://doi.org/10.1037/pha0000218.CrossRefPubMed

63.

Zale EL, Ditre JW, Dorfman ML, Heckman BW, Brandon TH. Smokers in pain report lower confidence and greater difficulty quitting. Nicotine Tob Res. 2014;16(9):1272–6. https://doi.org/10.1093/ntr/ntu077.CrossRefPubMedPubMedCentral

64.

Ditre JW, Langdon KJ, Kosiba JD, Zale EL, Zvolensky MJ. Relations between pain-related anxiety, tobacco dependence, and barriers to quitting among a community-based sample of daily smokers. Addict Behav. 2015;42:130–5. https://doi.org/10.1016/j.addbeh.2014.11.032.CrossRefPubMed

65.

Zale EL, Maisto SA, Ditre JW. Anxiety and depression in bidirectional relations between pain and smoking: implications for smoking cessation. Behav Modif. 2016;40(1–2):7–28. https://doi.org/10.1177/0145445515610744.CrossRefPubMed

66.

Zale EL, Ditre JW. Associations between chronic pain status, attempts to quit smoking, and use of pharmacotherapy for smoking cessation. Psychol Addict Behav. 2014;28(1):294–9. https://doi.org/10.1037/a0032515.CrossRefPubMed

67.

Hooten WM, Townsend CO, Hays JT, Ebnet KL, Gauvin TR, Gehin JM, et al. A cognitive behavioral smoking abstinence intervention for adults with chronic pain: a randomized controlled pilot trial. Addict Behav. 2014;39(3):593–9. https://doi.org/10.1016/j.addbeh.2013.11.010.CrossRefPubMed

68.

Montbriand JJ, Weinrib AZ, Azam MA, Ladak SSJ, Shah BR, Jiang J, et al. Smoking, pain intensity, and opioid consumption 1–3 months after major surgery: a retrospective study in a hospital-based transitional pain service. Nicotine Tob Res. 2018;20(9):1144–51. https://doi.org/10.1093/ntr/ntx094.CrossRefPubMed

69.

Miller ME, Sigmon SC. Are pharmacotherapies ineffective in opioid-dependent smokers? Reflections on the scientific literature and future directions. Nicotine Tob Res. 2015;17(8):955–9. https://doi.org/10.1093/ntr/ntv030.CrossRefPubMedPubMedCentral

70.

Herzog JI, Schmahl C. Adverse childhood experiences and the consequences on neurobiological, psychosocial, and somatic conditions across the lifespan. Front Psychiatry. 2018;9(420). https://doi.org/10.3389/fpsyt.2018.00420.

71.

Stein MD, Conti MT, Kenney S, Anderson BJ, Flori JN, Risi MM, et al. Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder. Drug Alcohol Depend. 2017;179:325–9. https://doi.org/10.1016/j.drugalcdep.2017.07.007.CrossRefPubMedPubMedCentral

72.

Shin SH, McDonald SE, Conley D. Patterns of adverse childhood experiences and substance use among young adults: a latent class analysis. Addict Behav. 2018;78:187–92. https://doi.org/10.1016/j.addbeh.2017.11.020.CrossRefPubMed

73.

Anda RF, Croft JB, Felitti VJ, Nordenberg D, Giles WH, Williamson DF, et al. Adverse childhood experiences and smoking during adolescence and adulthood. JAMA. 1999;282(17):1652–8.CrossRef

74.

Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Public Health. 2017;2(8):e356–e66. https://doi.org/10.1016/S2468-2667(17)30118-4.CrossRefPubMed

75.

Oshri A, Kogan SM, Kwon JA, Wickrama KAS, Vanderbroek L, Palmer AA, et al. Impulsivity as a mechanism linking child abuse and neglect with substance use in adolescence and adulthood. Dev Psychopathol. 2018;30(2):417–35. https://doi.org/10.1017/S0954579417000943.CrossRefPubMed

76.

• Lutz PE, Gross JA, Dhir SK, Maussion G, Yang J, Bramoulle A, et al. Epigenetic regulation of the kappa opioid receptor by child abuse. Biol Psychiatry. 2018;84(10):751–61. https://doi.org/10.1016/j.biopsych.2017.07.012 This study reports epigenetic changes in KOR expression in association with child abuse, suggesting a novel mechanism whereby adverse childhood experiences may influence risk for opioid and nicotine use, as well as other psychopathology, later in development. CrossRefPubMed

77.

al’Absi M, Lemieux A, Westra R, Allen S. Early life adversity influences stress response association with smoking relapse. Psychopharmacology. 2017;234(22):3375–84. https://doi.org/10.1007/s00213-017-4724-4.CrossRefPubMedPubMedCentral

78.

Wu NS, Schairer LC, Dellor E, Grella C. Childhood trauma and health outcomes in adults with comorbid substance abuse and mental health disorders. Addict Behav. 2010;35(1):68–71. https://doi.org/10.1016/j.addbeh.2009.09.003.CrossRefPubMed

79.

Verplaetse TL, Moore KE, Pittman BP, Roberts W, Oberleitner LM, Smith PH, et al. Intersection of stress and gender in association with transitions in past year DSM-5 substance use disorder diagnoses in the United States. Chronic Stress (Thousand Oaks). 2018;2. https://doi.org/10.1177/2470547017752637.

80.

Jaremko KM, Sterling RC, Van Bockstaele EJ. Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance. J Subst Abus Treat. 2015;48(1):117–27. https://doi.org/10.1016/j.jsat.2014.08.006.CrossRef

81.

Mantsch JR, Baker DA, Funk D, Le AD, Shaham Y. Stress-induced reinstatement of drug seeking: 20 years of progress. Neuropsychopharmacology. 2016;41(1):335–56. https://doi.org/10.1038/npp.2015.142.CrossRefPubMed

82.

Bershad AK, Miller MA, Norman GJ, de Wit H. Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans. Horm Behav. 2018;102:41–7. https://doi.org/10.1016/j.yhbeh.2018.04.009.CrossRefPubMedPubMedCentral

83.

•• Evans CJ, Cahill CM. Neurobiology of opioid dependence in creating addiction vulnerability. F1000Res. 2016;5. https://doi.org/10.12688/f1000research.8369.1 This review presents a mechanistic model highlighting various ways that opioid exposure potentiates the development of addiction.

84.

Van Hedger K, Bershad AK, de Wit H. Pharmacological challenge studies with acute psychosocial stress. Psychoneuroendocrinology. 2017;85:123–33. https://doi.org/10.1016/j.psyneuen.2017.08.020.CrossRefPubMedPubMedCentral

85.

Moran LM, Kowalczyk WJ, Phillips KA, Vahabzadeh M, Lin JL, Mezghanni M, et al. Sex differences in daily life stress and craving in opioid-dependent patients. Am J Drug Alcohol Abuse. 2018;44(5):512–23. https://doi.org/10.1080/00952990.2018.1454934.CrossRefPubMedPubMedCentral

86.

Tomko RL, Saladin ME, Baker NL, McClure EA, Carpenter MJ, Ramakrishnan VR, et al. Sex differences in subjective and behavioral responses to stressful and smoking cues presented in the natural environment of smokers. Nicotine Tob Res. 2018. https://doi.org/10.1093/ntr/nty234.

87.

Kidorf M, Solazzo S, Yan H, Brooner RK. Psychiatric and substance use comorbidity in treatment-seeking injection opioid users referred from syringe exchange. J Dual Diagn. 2018:1–8. https://doi.org/10.1080/15504263.2018.1510148.

88.

Anderson RE, Hruska B, Boros AP, Richardson CJ, Delahanty DL. Patterns of co-occurring addictions, posttraumatic stress disorder, and major depressive disorder in detoxification treatment seekers: implications for improving detoxification treatment outcomes. J Subst Abus Treat. 2018;86:45–51. https://doi.org/10.1016/j.jsat.2017.12.009.CrossRef

89.

Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606–10.CrossRef

90.

Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S. The association between severity of depression and prescription opioid misuse among chronic pain patients with and without anxiety: a cross-sectional study. J Affect Disord. 2018;235:293–302. https://doi.org/10.1016/j.jad.2018.04.058.CrossRefPubMed

91.

Grattan A, Sullivan MD, Saunders KW, Campbell CI, Von Korff MR. Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012;10(4):304–11. https://doi.org/10.1370/afm.1371.CrossRefPubMedPubMedCentral

92.

Serre F, Fatseas M, Denis C, Swendsen J, Auriacombe M. Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiate addictions: commonalities and specificities across substances. Addict Behav. 2018;83:123–9. https://doi.org/10.1016/j.addbeh.2018.01.041.CrossRefPubMed

93.

Fatseas M, Serre F, Swendsen J, Auriacombe M. Effects of anxiety and mood disorders on craving and substance use among patients with substance use disorder: an ecological momentary assessment study. Drug Alcohol Depend. 2018;187:242–8. https://doi.org/10.1016/j.drugalcdep.2018.03.008.CrossRefPubMed

94.

Heckman BW, Kovacs MA, Marquinez NS, Meltzer LR, Tsambarlis ME, Drobes DJ, et al. Influence of affective manipulations on cigarette craving: a meta-analysis. Addiction. 2013;108(12):2068–78. https://doi.org/10.1111/add.12284.CrossRefPubMed

95.

Litz M, Leslie D. The impact of mental health comorbidities on adherence to buprenorphine: a claims based analysis. Am J Addict. 2017;26(8):859–63. https://doi.org/10.1111/ajad.12644.CrossRefPubMed

96.

Zawertailo L, Voci S, Selby P. Depression status as a predictor of quit success in a real-world effectiveness study of nicotine replacement therapy. Psychiatry Res. 2015;226(1):120–7. https://doi.org/10.1016/j.psychres.2014.12.027.CrossRefPubMed

97.

Chisolm MS, Tuten M, Brigham EC, Strain EC, Jones HE. Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am J Addict. 2009;18(5):422–9. https://doi.org/10.3109/10550490903077721.CrossRefPubMedPubMedCentral

98.

Cooperman NA, Lu SE, Richter KP, Bernstein SL, Williams JM. Influence of psychiatric and personality disorders on smoking cessation among individuals in opiate dependence treatment. J Dual Diagn. 2016;12(2):118–28. https://doi.org/10.1080/15504263.2016.1172896.CrossRefPubMedPubMedCentral

99.

Boettger MK, Schwier C, Bar KJ. Sad mood increases pain sensitivity upon thermal grill illusion stimulation: implications for central pain processing. Pain. 2011;152(1):123–30. https://doi.org/10.1016/j.pain.2010.10.003.CrossRefPubMed

100.

• Thompson T, Correll CU, Gallop K, Vancampfort D, Stubbs B. Is pain perception altered in people with depression? A systematic review and meta-analysis of experimental pain research. J Pain. 2016;17(12):1257–72. https://doi.org/10.1016/j.jpain.2016.08.007 This review presents results from a meta-analysis of 32 studies on pain perception in depression and highlights an important influence of painful stimulus type (cutaneous vs. ischemic pain). CrossRefPubMed

101.

Wasan AD, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005;117(3):450–61. https://doi.org/10.1016/j.pain.2005.08.006.CrossRefPubMed

102.

Carcoba LM, Contreras AE, Cepeda-Benito A, Meagher MW. Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. J Addict Dis. 2011;30(3):258–70. https://doi.org/10.1080/10550887.2011.581985.CrossRefPubMedPubMedCentral

103.

American Psychological Association. Guidelines for psychological practice with lesbian, gay, and bisexual clients. Am Psychol. 2012;67(1):10–42.CrossRef

104.

Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res. 1999;1(4):301–15. https://doi.org/10.1080/14622299050011431.CrossRefPubMed

105.

Zakiniaeiz Y, Potenza MN. Gender-related differences in addiction: a review of human studies. Curr Opin Behav Sci. 2018;23:171–5. https://doi.org/10.1016/j.cobeha.2018.08.004.CrossRef

106.

Perkins KA, Jacobs L, Sanders M, Caggiula AR. Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology. 2002;163(2):194–201. https://doi.org/10.1007/s00213-002-1168-1.CrossRefPubMed

107.

Perkins KA, Gerlach D, Vender J, Meeker J, Hutchison S, Grobe J. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res. 2001;3(2):141–50. https://doi.org/10.1080/14622200110043059.CrossRefPubMed

108.

Perkins KA. Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharmacol. 1996;4(2):166–77. https://doi.org/10.1037/1064-1297.4.2.166.CrossRef

109.

Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther. 2006;80(4):319–30. https://doi.org/10.1016/j.clpt.2006.06.011.CrossRefPubMed

110.

Sofuoglu M, Mooney M. Subjective responses to intravenous nicotine: greater sensitivity in women than in men. Exp Clin Psychopharmacol. 2009;17(2):63–9. https://doi.org/10.1037/a0015297.CrossRefPubMedPubMedCentral

111.

Bjornson W, Rand C, Connett JE, Lindgren P, Nides M, Pope F, et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health. 1995;85(2):223–30.CrossRef

112.

Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265–72. https://doi.org/10.1016/j.drugalcdep.2004.02.001.CrossRefPubMed

113.

Jamison RN, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender differences in risk factors for aberrant prescription opioid use. J Pain. 2010;11(4):312–20. https://doi.org/10.1016/j.jpain.2009.07.016.CrossRefPubMed

114.

Back SE, Payne RL, Simpson AN, Brady KT. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav. 2010;35(11):1001–7. https://doi.org/10.1016/j.addbeh.2010.06.018.CrossRefPubMedPubMedCentral

115.

Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36(8):829–34. https://doi.org/10.1016/j.addbeh.2011.03.013.CrossRefPubMedPubMedCentral

116.

Akerman SC, Brunette MF, Green AI, Goodman DJ, Blunt HB, Heil SH. Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. J Subst Abus Treat. 2015;52:40–7. https://doi.org/10.1016/j.jsat.2014.12.002.CrossRef

117.

SAMHSA. Substance use among women during pregnancy and following childbirth. In: The NSDUH Report: Office of Applied Studies, Substance Abuse and Mental Health Services Administration; 2009.

118.

Chisolm MS, Fitzsimons H, Leoutsakos JM, Acquavita SP, Heil SH, Wilson-Murphy M, et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tob Res. 2013;15(7):1297–304. https://doi.org/10.1093/ntr/nts274.CrossRefPubMedPubMedCentral

119.

Jones HE, Heil SH, O’Grady KE, Martin PR, Kaltenbach K, Coyle MG, et al. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. Am J Drug Alcohol Abuse. 2009;35(5):375–80. https://doi.org/10.1080/00952990903125235.CrossRefPubMedPubMedCentral

120.

Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Women’s Health (2002). 2003;12(4):373–80. https://doi.org/10.1089/154099903765448880.CrossRef

121.

Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy. 2017;37(7):824–39. https://doi.org/10.1002/phar.1958.CrossRefPubMed

122.

• Kota D, Alajaji M, Bagdas D, Selley DE, Sim-Selley LJ, Damaj MI. Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male mice. Pharmacol Biochem Behav. 2018;173:58–64. https://doi.org/10.1016/j.pbb.2018.08.006 This study finds adolescent nicotine exposure impacts MORs and opioid reward later in adulthood. CrossRefPubMed

123.

Smith RF, McDonald CG, Bergstrom HC, Ehlinger DG, Brielmaier JM. Adolescent nicotine induces persisting changes in development of neural connectivity. Neurosci Biobehav Rev. 2015;55:432–43. https://doi.org/10.1016/j.neubiorev.2015.05.019.CrossRefPubMed

124.

Marco EM, Granstrem O, Moreno E, Llorente R, Adriani W, Laviola G, et al. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur J Pharmacol. 2007;557(1):37–43. https://doi.org/10.1016/j.ejphar.2006.11.013.CrossRefPubMed

125.

Thanos P, Delis F, Rosko L, Volkow ND. Passive response to stress in adolescent female and adult male mice after intermittent nicotine exposure in adolescence. J Addict Res Ther. 2013;(Suppl 6):007. https://doi.org/10.4172/2155-6105.S6-007.

126.

Iniguez SD, Warren BL, Parise EM, Alcantara LF, Schuh B, Maffeo ML, et al. Nicotine exposure during adolescence induces a depression-like state in adulthood. Neuropsychopharmacology. 2009;34(6):1609–24. https://doi.org/10.1038/npp.2008.220.CrossRefPubMed

127.

Gentry S, Craig J, Holland R, Notley C. Smoking cessation for substance misusers: a systematic review of qualitative studies on participant and provider beliefs and perceptions. Drug Alcohol Depend. 2017;180:178–92. https://doi.org/10.1016/j.drugalcdep.2017.07.043.CrossRefPubMed

128.

McHugh RK, Votaw VR, Fulciniti F, Connery HS, Griffin ML, Monti PM, et al. Perceived barriers to smoking cessation among adults with substance use disorders. J Subst Abus Treat. 2017;74:48–53. https://doi.org/10.1016/j.jsat.2016.12.008.CrossRef

129.

• McKelvey K, Thrul J, Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: an updated and narrative review. Addict Behav. 2017;65:161–70. https://doi.org/10.1016/j.addbeh.2016.10.012 This review reports that smoking cessation does not negatively impact substance use outcomes as previously thought, rather the literature suggests a positive effect of treating smoking. CrossRefPubMed

130.

Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72(6):1144–56. https://doi.org/10.1037/0022-006X.72.6.1144.CrossRefPubMed

131.

Mannelli P, Wu LT, Peindl KS, Gorelick DA. Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine Tob Res. 2013;15(10):1705–13. https://doi.org/10.1093/ntr/ntt046.CrossRefPubMedPubMedCentral

132.

Shoptaw S, Rotheram-Fuller E, Yang X, Frosch D, Nahom D, Jarvik ME, et al. Smoking cessation in methadone maintenance. Addiction. 2002;97(10):1317–28 discussion 25.CrossRef

133.

Tacke U, Wolff K, Finch E, Strang J. The effect of tobacco smoking on subjective symptoms of inadequacy (“not holding”) of methadone dose among opiate addicts in methadone maintenance treatment. Addict Biol. 2001;6(2):137–45. https://doi.org/10.1080/13556210020040217.CrossRefPubMed

134.

•• Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The cholinergic system as a treatment target for opioid use disorder. CNS Drugs. 2018. https://doi.org/10.1007/s40263-018-0572-y This review presents preclinical and clinical data highlighting the potential of different cholinergic medications for the treatment OUD.

135.

•• Norman H, D’Souza MS. Endogenous opioid system: a promising target for future smoking cessation medications. Psychopharmacology (Berl). 2017;234(9–10):1371–94. https://doi.org/10.1007/s00213-017-4582-0 This review presents an overview of data suggesting that manipulation of the endogenous opioid system may aid smoking cessation from both animal and human literatures. CrossRef

136.

Diehl A, Nakovics H, Croissant B, Smolka MN, Batra A, Mann K. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther. 2006;44(12):614–22.CrossRef

137.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55. https://doi.org/10.1001/jama.296.1.47.CrossRefPubMed

138.

Hooten WM, Warner DO. Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Addict Behav. 2015;42:69–72. https://doi.org/10.1016/j.addbeh.2014.11.007.CrossRefPubMed

139.

Liu S, Li L, Shen W, Shen X, Yang G, Zhou W. Scopolamine detoxification technique for heroin dependence: a randomized trial. CNS Drugs. 2013;27(12):1093–102. https://doi.org/10.1007/s40263-013-0111-9.CrossRefPubMed

140.

David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. (2013, 6):CD003086. https://doi.org/10.1002/14651858.CD003086.pub3.

141.

David SP, Chu IM, Lancaster T, Stead LF, Evins AE, Prochaska JJ. Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ Open. 2014;4(3):e004393. https://doi.org/10.1136/bmjopen-2013-004393.CrossRefPubMedPubMedCentral

142.

Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology. 2014;231(19):3843–53. https://doi.org/10.1007/s00213-014-3519-0.CrossRefPubMedPubMedCentral

143.

Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis. 2008;27(1):65–72. https://doi.org/10.1300/J069v27n01_07.CrossRefPubMed

Titel: Mechanisms and Clinical Features of Co-Occurring Opioid and Nicotine Use
verfasst von: Sarah D. Lichenstein
Yasmin Zakiniaeiz
Sarah W. Yip
Kathleen A. Garrison
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Current Addiction Reports / Ausgabe 2/2019
Elektronische ISSN: 2196-2952
DOI: https://doi.org/10.1007/s40429-019-00245-3

New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

Dissociation and Addictive Behaviors (J Billieux and A Schimmenti, Section Editors)

Dopamine and Gambling Disorder: Prospects for Personalized Treatment

Gambling (L Clark, Section Editor)

A Review of the Use and Appeal of Flavored Electronic Cigarettes

Tobacco (K Garrison, Section Editor)

E-Cigarettes: Tobacco Policy and Regulation

Tobacco (K Garrison, Section Editor)

Correction to: Social Media for Tobacco Smoking Cessation Intervention: a Review of the Literature

Correction

Correction to: New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

Correction

Neu im Fachgebiet Psychiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Psychologische Interventionen können Depressionen oft verhindern

16.12.2024
Depressive Störungen
Nachrichten

Gespräche, Telefonate, internetbasierte Verfahren: Mit solchen Methoden lässt sich der Beginn einer Depression bei gefährdeten Personen oft vermeiden. Sie funktionieren vor allem dann, wenn die Betroffenen deutliche Symptome aufweisen und noch keine Psychotherapie hatten.

Die beste Medizin gegen Altersdepression: Laufen, Lernen, Lachen, Lieben

13.12.2024
Altersdepression
Nachrichten

Depressionen im Alter haben vielfältige Ursachen und verlaufen anders als bei jungen Menschen. Ohne einen multimodalen Ansatz kommt man oft nicht weit: Neben Medikamenten und Psychotherapien ist die physische, kognitive und soziale Aktivierung entscheidend.

Wir sozio-emotionalen Blobs

13.12.2024
DGPPN 2024
Nachrichten

Entscheidungen sollten rational erfolgen – in der Politik wie im Leben. So wünschen wir uns das. Letztlich werden sie aber von Emotionen bestimmt. Wer das nicht versteht und anerkennt, wird kaum Wege aus Krisen finden. Die Neurowissenschaftlerin Maren Urner fordert daher eine „Reifeprüfung“ zur Krisenbewältigung.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Mechanisms and Clinical Features of Co-Occurring Opioid and Nicotine Use

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 2/2019

New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

Dopamine and Gambling Disorder: Prospects for Personalized Treatment

A Review of the Use and Appeal of Flavored Electronic Cigarettes

E-Cigarettes: Tobacco Policy and Regulation

Correction to: Social Media for Tobacco Smoking Cessation Intervention: a Review of the Literature

Correction to: New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues

Neu im Fachgebiet Psychiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Psychologische Interventionen können Depressionen oft verhindern

Die beste Medizin gegen Altersdepression: Laufen, Lernen, Lachen, Lieben

Wir sozio-emotionalen Blobs

Update Psychiatrie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten